CP
REGN icon

Corbenic Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Corbenic Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5
Closed -$3K – 308
2021
Q3 		$3K Buy
+5
New +$3.1K ﹤0.01% 237
2017
Q4 		– Sell
-20
Closed -$9K – 234
2017
Q3 		$9K Buy
+20
New +$9.52K 0.01% 157

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Corbenic Partners's REGN Position: Q4 2021 in Review

Corbenic Partners sold out of Regeneron Pharmaceuticals (REGN) in Q4 2021, closing a stake of 5 shares — an estimated $3K sold.

Corbenic Partners first reported a position in REGN in Q3 2017 and held it in 2 quarters. The position peaked at $9K in Q3 2017. 1,078 funds tracked by Wall St. Rank hold REGN as of Q4 2021.

  • Corbenic Partners reported no remaining Regeneron Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Corbenic Partners sold 5 Regeneron Pharmaceuticals shares in Q4 2021, an estimated $3K.
  • Corbenic Partners first reported a position in Regeneron Pharmaceuticals in Q3 2017 and held it in 2 quarters.
  • Corbenic Partners's Regeneron Pharmaceuticals position peaked at $9K in Q3 2017.
  • 1,078 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2021.

Based on Corbenic Partners's 13F filing for Q4 2021, filed 21 Jan 2022.